8-K: McKesson Corporation Reports Strong Q3 Results and Raises Full Year Guidance

McKesson Corporation announced a 15% increase in third-quarter revenue and raised its full-year adjusted earnings per diluted share guidance.

Summary

• McKesson Corporation reported a 15% increase in consolidated revenues to $80.9 billion for the third quarter of fiscal year 2024.
• Earnings per diluted share from continuing operations decreased by $3.23 to $4.42, primarily due to a $515 million pre-tax increase in bad debt provisions related to the Rite Aid bankruptcy.
• Adjusted earnings per diluted share increased by 12% to $7.74, driven by a lower tax rate, reduced share count, and growth in the U.S. Pharmaceutical and Prescription Technology Solutions segments.
• The company has raised its full-year adjusted earnings per diluted share guidance to a range of $27.25 to $27.65, up from the previous range of $26.80 to $27.40.
• For the first nine months of the fiscal year, McKesson returned $2.6 billion to shareholders through share repurchases and dividend payments.
• The company generated $167 million in cash from operations and invested $418 million in capital expenditures, resulting in negative free cash flow of $251 million for the first nine months of the fiscal year.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth and increased earnings guidance, but tempered by the negative impact of the Rite Aid bankruptcy and negative free cash flow.

Positives

• McKesson experienced strong revenue growth across its North American businesses.
• The company's adjusted earnings per diluted share increased by 12% in the third quarter.
• The full-year adjusted earnings per diluted share guidance has been raised, indicating positive future expectations.
• The U.S. Pharmaceutical and Prescription Technology Solutions segments showed strong growth.
• McKesson has demonstrated a commitment to returning value to shareholders through share repurchases and dividends.
• The company has received multiple awards and recognitions for its commitment to sustainability and diversity.

Negatives

• Earnings per diluted share from continuing operations decreased by $3.23 due to a significant increase in bad debt provisions related to the Rite Aid bankruptcy.
• The Medical-Surgical Solutions segment's adjusted operating profit decreased by 16%.
• The International segment experienced a significant revenue decrease due to divestitures in Europe.
• Free cash flow was negative $251 million for the first nine months of the fiscal year.

Risks

• The Rite Aid bankruptcy significantly impacted earnings due to a $515 million pre-tax increase in bad debt provisions.
• Divestitures in the European business led to a decrease in revenue for the International segment.
• The company's free cash flow was negative for the first nine months of the fiscal year.
• The company is subject to various risks including legal disputes, cybersecurity incidents, and changes in healthcare laws.

Future Outlook

McKesson has raised its full-year adjusted earnings per diluted share guidance to $27.25 to $27.65, reflecting solid operating performance and a growth rate of 5% to 7%. The company does not provide forward-looking guidance on a GAAP basis.

Management Comments

• McKesson delivered another quarter of solid results, led by growth across our North American businesses.
• These results are reflective of the commitment to our company priorities and growth strategies, delivering differentiated solutions and value in oncology and biopharma services.
• As a result of our third quarter performance and solid operating momentum, we are raising and narrowing our guidance range for fiscal 2024 Adjusted Earnings per Diluted Share to $27.25 to $27.65.

Industry Context

McKesson's performance reflects the ongoing trends in the healthcare industry, including increased demand for specialty pharmaceuticals and technology solutions. The company's expansion in oncology services and its focus on biopharma services align with the industry's growth areas. The impact of the Rite Aid bankruptcy highlights the financial risks associated with customer solvency in the pharmaceutical distribution sector.

Comparison to Industry Standards

• McKesson's 15% revenue growth in the third quarter is strong compared to some of its peers in the pharmaceutical distribution industry, such as Cardinal Health and AmerisourceBergen, which have reported lower growth rates in recent quarters.
• The 12% increase in adjusted earnings per diluted share is also a positive indicator, suggesting efficient cost management and operational improvements.
• However, the negative free cash flow of $251 million for the first nine months of the fiscal year is a concern, as many of its peers are generating positive free cash flow.
• The impact of the Rite Aid bankruptcy on McKesson's earnings highlights the risks associated with customer credit and the importance of robust risk management practices, which is a common challenge in the industry.
• The company's expansion in oncology services is in line with the industry's focus on high-growth areas, similar to other companies investing in specialty pharmaceuticals and related services.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased full-year adjusted earnings per diluted share guidance and the return of capital through share repurchases and dividends.
• Employees are recognized for their contributions to the company's performance and commitment to its strategy.
• Customers may be impacted by the company's focus on differentiated solutions and value in oncology and biopharma services.
• Suppliers may be affected by changes in the company's business strategies and operational performance.
• Creditors may be impacted by the company's financial performance and its ability to meet its obligations.

Next Steps

• McKesson management will participate in the Barclays Global Healthcare Conference in March 2024.
• McKesson management will participate in the BofA Securities 2024 Healthcare Conference in May 2024.
• The company will continue to execute its growth strategies and focus on delivering value to stakeholders.

Key Dates

Keywords

McKesson, Pharmaceutical, Healthcare, Earnings, Revenue, Guidance, Oncology, Prescription Technology, Medical-Surgical, Financial Results